Oxford Immunotec Global PLC (OXFD) Trading 3.7% Higher
Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) traded up 3.7% during trading on Tuesday . The stock traded as high as $9.80 and last traded at $9.62, with a volume of 174,175 shares changing hands. The stock had previously closed at $9.28.
Several analysts recently commented on the stock. Piper Jaffray Cos. reiterated a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Sunday, June 26th. Zacks Investment Research upgraded shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, BTIG Research reiterated a “buy” rating and issued a $17.00 price target on shares of Oxford Immunotec Global PLC in a research report on Tuesday, August 2nd.
The company’s 50 day moving average is $8.83 and its 200-day moving average is $9.74. The firm’s market capitalization is $223.43 million.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.29) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. The business earned $19.20 million during the quarter, compared to analysts’ expectations of $18.10 million. During the same quarter in the previous year, the business posted ($0.33) EPS. The company’s quarterly revenue was up 34.3% on a year-over-year basis. Analysts forecast that Oxford Immunotec Global PLC will post ($1.28) earnings per share for the current year.
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.